Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of PBI-4547 in Healthy Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2020
Price :
$35
*
At a glance
- Drugs PBI 4547 (Primary)
- Indications Diabetes mellitus; Hepatic fibrosis; Metabolic syndrome; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity
- Focus Adverse reactions; First in man
- Sponsors Liminal BioSciences
- 17 Jun 2020 Status changed from suspended to discontinued.
- 06 Dec 2019 Planned End Date changed from 6 Nov 2019 to 8 Sep 2020.
- 06 Dec 2019 Planned primary completion date changed from 6 Nov 2019 to 8 Sep 2020.